Prospective, International, Multicenter, Observational Study to Evaluate the Clinical Performance and Safety of a Silicone-coated Transparent Postoperative Dressing

Sponsor
BSN Medical GmbH (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04775316
Collaborator
(none)
75
3
15.9
25
1.6

Study Details

Study Description

Brief Summary

Although, a huge number of acute wounds is treated successfully every year, Health Care Professionals (HCPs) are facing more and more problems when treating skin damages or surgical incisions: The number of patients with fragile and/or sensitive skin is highly increasing. Such patients are having a skin integrity issue, meaning the skin is vulnerable to injury, often damaged, or unable to heal.

The investigational medical devices (IMDs) of the planned clinical evaluation, Leukomed® T skin sensitive and Leukomed® T plus skin sensitive have been developed for treatment of acute wounds on patients with fragile or sensitive skin to provide a reliable but skin-friendly fixation and wound care option.

The primary purpose of this clinical study is the evaluation of clinical performance to stay in place up to seven days and the safety of both dressings. Further, data on wearing comfort, product handling, pain during removal and quality of life are considered as secondary outcomes. The products will be used as part of routine wound care within the scope of their intended purpose without any additional invasive or burdensome examination.

Condition or Disease Intervention/Treatment Phase
  • Device: Leukomed T / Tplus skin sensitive treatment

Study Design

Study Type:
Observational
Anticipated Enrollment :
75 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
C2654 - Prospective, International, Multicenter, Observational Study to Evaluate the Clinical Performance and Safety of a Silicone-coated Transparent Postoperative Dressing
Actual Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Aug 28, 2022
Anticipated Study Completion Date :
Dec 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Patients with fragile skin

Patient aged 65 years and older presenting with fragile skin and require wound care of an acute wound (laceration or surgical wound). Siliconized sterile wound dressing will be applied for a treatment period of 7 days.

Device: Leukomed T / Tplus skin sensitive treatment
Application of sterile wound dressing.

Outcome Measures

Primary Outcome Measures

  1. Adhered dressing area after wear [7 days after dressing application]

    Percentage of adhered dressing area 7 days after application

Secondary Outcome Measures

  1. Skin damage [7 days after dressing application]

    skin damage after dressing removal

  2. Skin reddening [7 days after dressing application]

    Reddening of the skin 30 min after dressing removal

  3. Skin reactions [after 7 days]

    Further skin reactions after dressing removal

  4. Pain assessment [7 days after dressing application]

    Pain at dressing removal

  5. Product Evaluation by patient [7 days after dressing application]

    Judge wearing comfort

  6. Product Evaluation by Health Care Professional [at application day (day 0)]

    Assessment of handling, application and and re-application

  7. Infection [7 days after dressing application]

    Assess signs of wound infection

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Men, women or diverse

  • ≥ 65 years of age

  • Patient is mentally and physically able to participate in this study

  • Signed informed consent to participate in this study

  • Fragile skin condition

  • Acute wound (surgical wound or laceration), indicated for treatment with the investigational products for a time period of 7 days

Exclusion Criteria:
  • Infection of the target wound

  • Alcohol or drug addiction

  • Known sensitivity or allergy to any component of the study product

  • Patients who participate in any other clinical study investigating drugs or medical devices

Contacts and Locations

Locations

Site City State Country Postal Code
1 Practice Degenhardt Bremen Germany
2 Klinikum Dortmund Dortmund Germany
3 orthoGroup Hamburg Germany

Sponsors and Collaborators

  • BSN Medical GmbH

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
BSN Medical GmbH
ClinicalTrials.gov Identifier:
NCT04775316
Other Study ID Numbers:
  • C2654
First Posted:
Mar 1, 2021
Last Update Posted:
Apr 22, 2022
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 22, 2022